Abstract
Glia are key players in a number of nervous system disorders. Besides releasing glial and neuronal signaling molecules directed to cellular homeostasis, glia respond also to pro-inflammatory signals released from immune-related cells, with the mast cell being of particular interest. A proposed mast cell–glia communication may open new perspectives for designing therapies to target neuroinflammation by differentially modulating activation of non-neuronal cells normally controlling neuronal sensitization—both peripherally and centrally. Mast cells and glia possess endogenous homeostatic mechanisms/molecules that can be upregulated as a result of tissue damage or stimulation of inflammatory responses. Such molecules include the N-acylethanolamines, whose principal family members are the endocannabinoid N-arachidonoylethanolamine (anandamide), and its congeners N-stearoylethanolamine, N-oleoylethanolamine, and N-palmitoylethanolamine (PEA). A key role of PEA may be to maintain cellular homeostasis when faced with external stressors provoking, for example, inflammation: PEA is produced and hydrolyzed by microglia, it downmodulates mast cell activation, it increases in glutamate-treated neocortical neurons ex vivo and in injured cortex, and PEA levels increase in the spinal cord of mice with chronic relapsing experimental allergic encephalomyelitis. Applied exogenously, PEA has proven efficacious in mast cell-mediated experimental models of acute and neurogenic inflammation. This fatty acid amide possesses also neuroprotective effects, for example, in a model of spinal cord trauma, in a delayed post-glutamate paradigm of excitotoxic death, and against amyloid β-peptide-induced learning and memory impairment in mice. These actions may be mediated by PEA acting through “receptor pleiotropism,” i.e., both direct and indirect interactions of PEA with different receptor targets, e.g., cannabinoid CB2 and peroxisome proliferator-activated receptor-alpha.
Similar content being viewed by others
References
Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F (2002) β-Amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo. Involvement of the p38MAPK pathway. Neurobiol Dis 11:257–274. doi:10.1006/nbdi.2002.0538
Dauer W, Przedborski S (2003) Parkinson disease. Mechanisms and models. Neuron 39:889–909. doi:10.1016/S0896-6273(03)00568-3
Gao HM, Liu B, Zhang W, Hong JS (2003) Novel anti-inflammatory therapy for Parkinson disease. Trends Pharmacol Sci 24:395–401. doi:10.1016/S0165-6147(03)00176-7
Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG (2003) Amyloid β peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport 14:1429–1433. doi:10.1097/01.wnr.0000086097.47480.a0
Barnum CJ, Tansey MG (2010) Modeling neuroinflammatory pathogenesis of Parkinson disease. Prog Brain Res 184:113–132. doi:10.1016/S0079-6123(10)84006-3
Qureshi GA, Baig S, Bednar I, Södersten P, Forsberg G, Siden A (1995) Increased cerebrospinal fluid concentration of nitrite in Parkinson disease. Neuroreport 6:1642–1644
Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB (2000) Deficiency of inducible nitric-oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74:2213–2216. doi:10.1046/j.1471-4159.2000.0742213.x
Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson disease. J Neural Transm Suppl 60:277–290
Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K (2007) Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson disease. Proc Natl Acad Sci USA 104:18754–18759. doi:10.1073/pnas.0704908104
Mondal S, Roy A, Jana A, Ghosh S, Kordower JH, Pahan K (2012) Testing NF-κB-based therapy in hemiparkinsonian monkeys. J Neuroimmune Pharmacol 7:544–556. doi:10.1007/s11481-012-9377-9
Skaper SD, Giusti P (2009) P2X7 receptors as a transducer in the co-occurrence of neurological/psychiatric and cardiovascular aisorders: a hypothesis. Cardiovasc Psychiatry Neurol 2009:545263. doi:10.1155/2009/545263
Rivat C, Becker C, Blugeot A, Zeau B, Mauborgne A, Pohl M, Benoliel JJ (2010) Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia. Pain 150:358–368. doi:10.1016/j.pain.2010.05.031
Vichaya EG, Young EE, Frazier MA, Cook JL, Welsh CJ, Meagher MW (2011) Social disruption induced priming of CNS inflammatory response to Theiler's virus is dependent upon stress induced IL-6 release. J Neuroimmunol 239:44–52. doi:10.1016/j.jneuroim.2011.08.006
González-Scarano F, Baltuch G (1999) Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22:219–240. doi:10.1146/annurev.neuro.22.1.219
Sailasuta N, Harris K, Tran T, Ross B (2011) Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study. Neuropsychiatr Dis Treat 7:495–499. doi:10.2147/NDT.S23721
Barcia C, Ros CM, Annese V, Gómez A, Ros-Bernal F, Aguado-Yera D, Martínez-Pagán ME, de Pablos V, Fernandez-Villalba E, Herrero MT (2011) IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis 2:e142. doi:10.1038/cddis.2011.17
Appel SH, Zhao W, Beers DR, Henkel JS (2011) The microglial-motoneuron dialogue in ALS. Acta Myol 30:4–8
Mitterauer BJ (2011) Possible role of glia in cognitive impairment in schizophrenia. CNS Neurosci Ther 17:333–344. doi:10.1111/j.1755-5949.2009.00113.x
Hinwood M, Morandini J, Day TA, Walker FR (2012) Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cereb Cortex 22:1442–1454
Rosano C, Marsland AL, Gianaros PJ (2012) Maintaining brain health by monitoring inflammatory processes: a mechanism to promote successful aging. Aging Dis 3:16–33
Jha MK, Jeon S, Suk K (2012) Glia as a link between neuroinflammation and neuropathic pain. Immune Netw 12:41–47. doi:10.4110/in.2012.12.2.41
Carson MJ (2002) Microglia as liaisons between the immune and central nervous systems. Functional implications for multiple sclerosis. Glia 40:218–231. doi:10.1002/glia.10145
Chen CC, Grimbaldeston MA, Tsai M, Weissman IL, Galli SJ (2005) Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci USA 102:11408–11413. doi:10.1073/pnas.0504197102
Gilfillan AM, Austin SJ, Metcalfe DD (2011) Mast cell biology: introduction and overview. Adv Exp Med Biol 716:2–12. doi:10.1038/ni1158
Lambracht-Hall M, Dimitriadou V, Theoharides TC (1990) Migration of mast cells in the developing rat brain. Dev Brain Res 56:151–159. doi:10.1016/0165-3806(90)90077-C
Silverman AJ, Sutherland AK, Wilhelm M, Silver R (2000) Mast cells migrate from blood to brain. J Neurosci 20:401–408
Engler H, Doenlen R, Engler A, Riether C, Prager G, Niemi MB, Pacheco-López G, Krügel U, Schedlowski M (2011) Acute amygdaloid response to systemic inflammation. Brain Behav Immun 25:1384–1392. doi:10.1016/j.bbi.2011.04.005
Moreno B, Jukes JP, Vergara-Irigaray N, Errea O, Villoslada P, Perry VH, Newman TA (2011) Systemic inflammation induces axon injury during brain inflammation. Ann Neurol 70:932–942. doi:10.1002/ana.22550
Johnson D, Krenger W (1992) Interactions of mast cells with the nervous system—recent advances. Neurochem Res 17:939–951. doi:10.1007/BF00993271
Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6:135–142. doi:10.1038/ni1158
Wardlaw AJ, Moqbel R, Cromwell O, Kay AB (1986) Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 78:1701–1706. doi:10.1172/JCI112765
Perry VH, Andersson P-B, Gordon G (1993) Macrophages and inflammation in the central nervous system. Trends Neurosci 16:268–273. doi:10.1016/0166-2266(93)90180-T
Johnson D, Yasui D, Seeldayers P (1991) An analysis of mast cell frequency in the rodent nervous system: numbers vary between different strains and can be reconstituted in mast cell-deficient mice. J Neuropathol Exp Neurol 50:227–234. doi:10.1097/00005072-19910005-00005
Brenner T, Soffer D, Shalit M, Levi-Schaffer F (1994) Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J Neurol Sci 122:210–213. doi:10.1016/0022-510X(94)90300-X
Theoharides TC (1990) Mast cells: the immune gate to the brain. Life Sci 46:607–617. doi:10.1016/0024-3205(90)90129-F
Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC (1995) Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 37:63–66. doi:10.1002/ana.410370112
Medic N, Vita F, Abbate R, Soranzo MR, Pacor S, Fabbretti E, Borelli V, Zabucchi G (2008) Mast cell activation by myelin through scavenger receptor. J Neuroimmunol 200:27–40. doi:10.1016/j.jneuroim.2008.05.019
Skaper SD, Facci L, Romanello S, Leon A (1996) Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J Neurochem 66:1157–1166. doi:10.1046/j.1471-4159.1996.66031157.x
Theoharides TC, Baloyannis SJ, Manolidis LS (1991) Activated rat peritoneal mast cells can cause syngeneic brain demyelination in vitro. Int J Immunopathol Pharmacol 4:137–144
Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R (2008) Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci USA 105:18053–18057. doi:10.1073/pnas.0809479105
DeLeo JA, Yezierski RP (2001) The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90:1–6. doi:10.1016/S0304-3959(0)00490-5
Watkins LR, Milligan ED, Maier SF (2001) Spinal cord glia: new players in pain. Pain 93:201–205. doi:10.1016/S0304-3959(01)00359-1
Watkins LR, Milligan ED, Maier SF (2003) Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol 521:1–21
Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S, Inoue K (2008) P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J Neurosci 28:4949–4956. doi:10.1523/JNEUROSCI.0323-08.2008
Burnstock G, Krügel U, Abbracchio MP, Illes P (2011) Purinergic signalling: from normal behaviour to pathological brain function. Prog Neurobiol 95:229–274. doi:10.1016/j.pneurobio.2011.08.006
Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN (2005) Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114:386–396. doi:10.1016/j.pain.2005.01.002
Tsuda M, Kuboyama K, Inoue T, Nagata K, Tozaki-Saitoh H, Inoue K (2009) Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays. Mol Pain 5:28. doi:10.1186/1744-8069-5-28
Ji RR, Gereau RW 4th, Malcangio M, Strichartz GR (2009) MAP kinase and pain. Brain Res Rev 60:135–148. doi:10.1016/j.brainresrev.2008.12.011
Xanthos DN, Gaderer S, Drdla R, Nuro E, Abramova A, Ellmeier W, Sandkühler J (2011) Central nervous system mast cells in peripheral inflammatory nociception. Mol Pain 7:42. doi:10.1186/1744-8069-7-42
Zuo Y, Perkins NM, Tracey DJ, Geczy CL (2003) Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. Pain 105:467–479. doi:10.1016/S0304-3959(03)00261-6
Levy D, Kainz V, Burstein R, Strassman AM (2012) Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity. Brain Behav Immun 26:311–317. doi:10.1016/j.bbi.2011.09.016
Koda H, Mizumura K (2002) Sensitization to mechanical stimulation by inflammatory mediators and by mild burn in canine visceral nociceptors in vitro. J Neurophysiol 87:2043–2051. doi:10.1152/jn.00593.2001
Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, Levi-Montalcini R (1994) Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci USA 91:3739–3743. doi:10.1073/pnas.91.9.3739
Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A (1996) Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 19:514–520. doi:10.1016/S0166-2236(96)10058-8
Vallières L, Rivest S (1997) Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine interleukin-1β. J Neurochem 69:1668–1683. doi:10.1046/j.1471-4159.1997.69041668.x
Leal-Berumen I, Conlon P, Marshall JS (1994) IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J Immunol 152:5468–5476
Hayashi R, Xiao W, Kawamato M, Yuge O, Bennett GJ (2011) Systemic glucocorticoid therapy reduces pain and the number of endoneurial tumor necrosis factor-alpha (TNFα)-positive mast cells in rats with a painful peripheral neuropathy. J Pharmacol Sci 106:559–565. doi:10.1254/jphs.FP0072181
Wang Q, Tang XN, Yenari MA (2007) The inflammatory response in stroke. J Neuroimmunol 184:53–68. doi:10.1016/j.jneuroim.2006.11.014
Hanisch U-K, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10:1387–1394. doi:10.1038/nn1997
Silver R, Silverman A, Vitkovic L, Lederhendler I (1996) Mast cells in the brain: evidence and functional significance. Trends Neurosci 19:25–31. doi:10.1016/0166-2236(96)81863-7
Michaloudi H, Grivas I, Batzios C, Chiotelli M, Papadopoulos G (2003) Parallel development of blood vessels and mast cells in the lateral geniculate nuclei. Brain Res Develop Brain Res 140:269–276. doi:10.1016/S0165-3806(02)00613-2
Chew LJ, Takanohashi A, Bell M (2006) Microglia and inflammation: impact on developmental brain injuries. Ment Retard Dev Disabil Res Rev 12:105–112. doi:10.1002/mrdd.20102
Jin Y, Silverman AJ, Vannucci SJ (2009) Mast cells are early responders after hypoxia-ischemia in immature rat brain. Stroke 40:3107–3112. doi:10.1161/STROKEAHA.109.549691
Gordon JR, Galli SJ (1991) Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses. J Exp Med 174:103–107. doi:10.1084/174.1.103
Gregersen R, Lambertsen K, Finsen B (2000) Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 20:53–65. doi:10.1097/00004647-200001000-00009
Hallenbeck JM (2002) The many faces of tumor necrosis factor in stroke. Nat Med 8:1363–1368. doi:10.1038/nm1202-1363
Jin Y, Silverman AJ, Vannucci SJ (2007) Mast cell stabilization limits hypoxic-ischemic brain damage in the immature rat. Dev Neurosci 29:373–384. doi:10.1159/000105478
Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ (2006) Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 26:605–612. doi:10.1038/sj.jcbfm.9600228
Biran V, Cochois V, Karroubi A, Arrang JM, Charriaut-Marlangue C, Heron A (2008) Stroke induces histamine accumulation and mast cell degranulation in the neonatal rat brain. Brain Pathol 18:1–9. doi:10.1111/j.1750-3639.2007.00092.x
Lozada A, Maegele M, Stark H, Neugebauer EM, Panula P (2005) Traumatic brain injury results in mast cell increase and changes in regulation of central histamine receptors. Neuropathol Appl Neurobiol 31:150–162. doi:10.1111/j.1365-2990.2004.00622.x
Lindsberg PJ, Strbian D, Karjalainen-Lindsberg ML (2010) Mast cells as early responders in the regulation of acute blood–brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab 30:689–702. doi:10.1038/jcbfm.2009.282
Mattila OS, Strbian D, Saksi J, Pikkarainen TO, Rantanen V, Tatlisumak T, Lindsberg PJ (2011) Cerebral mast cells mediate blood–brain barrier disruption in acute experimental ischemic stroke through perivascular gelatinase activation. Stroke 42:3600–3605. doi:10.1161/STROKEAHA.111.632224
Kim SU, de Vellis J (2005) Microglia in health and disease. J Neurosci Res 81:302–313. doi:10.1002/jnr.20562
Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hövelmeyer N, Waisman A, Rülicke T, Prinz M, Priller J, Becher B, Aguzzi A (2005) Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 11:146–152. doi:10.1038/nm1177
Filbin MT (2003) Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci 4:703–713. doi:10.1038/nrn1195
Olah M, Amor S, Brouwer N, Vinet J, Eggen B, Biber K, Boddeke HW (2012) Identification of a microglia phenotype supportive of remyelination. Glia 60:306–321. doi:10.1002/glia.21266
Secor VH, Secor WE, Gutekunst CA, Brown MA (2000) Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 191:813–822. doi:10.1084/jem.191.5.813
Tanzola MB, Robbie-Ryan M, Gutekunst CA, Brown MA (2003) Mast cells exert effects outside the central nervous system to influence experimental allergic encephalomyelitis disease course. J Immunol 171:4385–4391
Bennett JL, Blanchet MR, Zhao L, Zbytnuik L, Antignano F, Gold M, Kubes P, McNagny KM (2009) Bone marrow-derived mast cells accumulate in the central nervous system during inflammation but are dispensable for experimental autoimmune encephalomyelitis pathogenesis. J Immunol 182:5507–5514. doi:10.4049/jimmunol.0801485
Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12:1005–1015. doi:10.1038/nm1474
Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 79:964–973. doi:10.1124/mol.111.071290
Fan R, Xu F, Previti ML, Davis J, Grande AM, Robinson JK, Van Nostrand WE (2007) Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci 27:3057–3063. doi:10.1523/JNEUROSCI.4371-06.2007
Grathwohl SA, Kälin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M (2009) Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia. Nat Neurosci 12:1361–1363. doi:10.1038/nn.2432
Lalancette-Hébert M, Gowing G, Simard A, Weng YC, Kriz J (2007) Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci 27:2596–2605. doi:10.1523/JNEUROSCI.5360-06.2007
Imai F, Suzuki H, Oda J, Ninomiya T, Ono K, Sano H, Sawada M (2007) Neuroprotective effect of exogenous microglia in global brain ischemia. J Cereb Blood Flow Metab 27:488–500. doi:10.1038/sj.jcbfm.9600362
Vinet J, van Weering HR, Heinrich A, Kälin RE, Wegner A, Brouwer N, Heppner FL, van Rooijen N, Boddeke HW, Biber K (2012) Neuroprotective function for ramified microglia in hippocampal excitotoxicity. J Neuroinflammation 9:27. doi:10.1186/1742-2094-9-27
Tremblay ME, Lowery RL, Majewska AK (2010) Microglial interactions with synapses are modulated by visual experience. PLoS Biol 8:e1000527. doi:10.1371/journal.pbio.1000527
Lazarini F, Gabellec M-M, Torquet N, Lledo PM (2012) Early activation of microglia triggers long-lasting impairment of adult neurogenesis in the olfactory bulb. J Neurosci 32:3652–3664. doi:10.1523/JNEUROSCI.6394-11.2012
Skaper SD, Giusti P, Facci F (2012) Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 26:3103–3117. doi:10.1096/fj.11-197194
Hösli L, Hösli E, Schneider U, Wiget W (1984) Evidence for the existence of histamine H1- and H2-receptors on astrocytes of cultured rat central nervous system. Neurosci Lett 48:287–291. doi:10.1016/0304-3940(84)90052-1
Dong Y, Benveniste EN (2001) Immune function of astrocytes. Glia 36:180–190. doi:10.1002/glia.1107
Kim DY, Jeoung D, Ro JY (2010) Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis. J Immunol 185:273–283. doi:10.4049/jimmunol.1000991
Kim DY, Hong GU, Ro JY (2011) Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L. J Neuroinflammation 8:25. doi:10.1186/1742-2094-8-25
Gosselin RD, Suter MR, Ji RR, Decosterd I (2010) Glial cells and chronic pain. Neuroscientist 16:519. doi:10.1177/1073858409360822
Suk K, Ock J (2011) Chemical genetics of neuroinflammation: natural and synthetic compounds as microglial inhibitors. Inflammopharmacology 20:151. doi:10.1007/s10787-011-0108-2
Oliveira SM, Drewes CC, Silva CR, Trevisan G, Boschen SL, Moreira CG, de Almeida CD, Da Cunha C, Ferreira J (2011) Involvement of mast cells in a mouse model of postoperative pain. Eur J Pharmacol 672:88–95. doi:10.1016/j.ejphar.2011.10.001
Ralay Ranaivo H, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, Watterson DM (2006) Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26:662–670. doi:10.1523/JNEUROSCI.4652-05.2006
Pacher P, Bátkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389–462. doi:10.1124/pr.58.3.2
Sepe N, De Petrocellis L, Montanaro F, Cimino G, Di Marzo V (1998) Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. Biochim Biophys Acta 1389:101–111. doi:10.1016/S0005-2760(97)00132-X
Bisogno T, Ventriglia M, Milone A, Mosca M, Cimino G, Di Marzo V (1997) Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim Biophys Acta 1345:338–348. doi:10.1016/S0005-2760(97)00009-X
Matias I, Bisogno T, Melck D, Vandenbulcke F, Verger-Bocquet M, De Petrocellis L, Sergheraert C, Breton C, Di Marzo V, Salzet M (2001) Evidence for an endocannabinoid system in the central nervous system of the leech Hirudo medicinalis. Mol Brain Res 87:145–159. doi:10.1016/S0169-328X(00)00290-4
Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298–5305. doi:10.1074/jbc.M306642200
Coburn AF, Moore LV (1943) Nutrition as conditioning factor in the rheumatic state. Am J Dis Child 65:744–756
Coburn AF, Graham CE, Hahinger J (1954) Effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J Exp Med 100:425–435. doi:10.1084/jem.100.5.425
Kuehl FA Jr, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP (1957) The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J Am Chem Soc 79:5577–5578. doi:10.1021/ja01577a066
Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon L (1996) N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by downmodulating mast cell activation. Eur J Pharmacol 300:227–236. doi:10.1016/0014-2999(96)00015-5
Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394:277–281. doi:10.1038/28393
Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR (2001) Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42:321–327. doi:10.1046/j.1528-1157.2001.41499.x
Petrosino S, Iuvone T, Di Marzo V (2010) N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie 92:724–727. doi:10.1016/j.biochi.2010.01.006
Skaper SD (2012) Conference report: 1st workshop on “Palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator”. CNS Neurol Disord Drug Targets 11:191. doi:10.2174/187152712800672427
Muccioli GG, Stella N (2008) Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 54:16–22. doi:10.1016/j.neuropharm.2007.05.015
Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92:3376–3380. doi:10.1073/pnas.92.8.3376
Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A (2010) Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Vet Immunol Immunopathol 133:9–15. doi:10.1016/j.vetimm.2009.06.011
Hansen HS, Lauritzen L, Strand AM, Vinggaard AM, Frandsen A, Schousboe A (1997) Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. J Neurochem 69:753–761. doi:10.1061/j.1471-4159.1997.69020753x
Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N (2003) Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 23:7767–7775
Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH (2004) Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88:1159–1167. doi:10.1046/j.1471-4159.2003.02244.x
Schäbitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D (2002) Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33:2112–2114. doi:10.1161/01.STR.0000023491.63693.18
Ghafouri N, Ghafouri B, Larsson B, Turkina MV, Karlsson L, Fowler CJ, Gerdle B (2011) High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PLoS One 6:e27257. doi:10.1371/journal.pone.0027257
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300–302. doi:10.1096/fj.00-0399fje
Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G (2002) Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Brit J Pharmacol 135:181–187. doi:10.1038/sj.bjp.0704466
Jaggar SI, Hasnie FS, Sellaturay S, Rice AS (1998) The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76:189–199. doi:10.1016/S0304-3959(98)00041-4
Calignano A, La Rana G, Piomelli D (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419:191–198. doi:10.1016/S0014-2999(01)00988-8
Costa B, Conti S, Giagnoni G, Colleoni M (2002) Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 137:413–420. doi:10.1038/sj.bjp.0704900
Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S (2013) Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targets 12:45–54
D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, Meli R, Calignano A (2009) Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 613:54–59. doi:10.1016/j.ejphar.2009.04.022
De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T (2011) Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 10:3. doi:10.1186/1744-8069-7-3
Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J (2003) Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 73:2345–2353. doi:10.1016/S0024-3205(03)00651-9
Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G (2008) The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors. Pain 139:541–550. doi:10.1016/j.pain.2008.06.003
Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, Watanabe M, Guaza C, Di Marzo V, Molina-Holgado E (2009) The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 33:57–71. doi:10.1016/j.nbd.2008.09.015
Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S (2011) Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun 25:1099–1112. doi:10.1016/j.bbi.2011.02.006
Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S (2008) Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 326:12–23. doi:10.1124/jpet.108.136903
Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A (1996) The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 93:3984–3989. doi:10.1073/pnas,93.9.3984
D'Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A (2012) Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology 37:1784–1792. doi:10.1038/npp.2012.25
Scuderi C, Valenza M, Stecca C, Esposito G, Carratù MR, Steardo L (2012) Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α. J Neuroinflammation 9:49. doi:10.1186/1742-2094-9-21
Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev 11, CD008454. doi:10.1002/14651858.CD008454.pub2
Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T (2011) Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case–control study. Brit Med J 342:d198. doi:10.1136/bmj.d198
Esposito E, Impellizzeri D, Mazzon E, Paterniti I, Cuzzocrea S (2012) Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One 7(8):e41880. doi:10.1371/journal.pone.0041880
Ahmad A, Genovese T, Impellizzeri D, Crupi R, Velardi E, Marino A, Esposito E, Cuzzocrea S (2012) Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. Brain Res 1477:45–58. doi:10.1016/j.brainres.2012.08.006
Ahmad A, Crupi R, Impellizzeri D, Campolo M, Marino A, Esposito E, Cuzzocrea S (2012) Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun 26:1310–1321. doi:10.1016/j.bbi.2012.07.021
Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15–19. doi:10.1124/mol.104.006353
Raso GM, Esposito E, Vitiello S, Iacono A, Santoro A, D'Agostino G, Sasso O, Russo R, Piazza PV, Calignano A, Meli R (2011) Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-α. J Neuroendocrinol 23:591–600. doi:10.1111/j.1365-2826.2011.02152.x
Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L (2011) Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J Cell Mol Med 15:2664–2674. doi:10.1111/j.1582-4934.2011.01267.x
D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Raso GM, Cuzzocrea S, Lo Verme J, Piomelli D, Meli R, Calignano A (2007) Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 322:1137–1143. doi:10.1124/jpet.107.123265
de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R, Marabese I, D'Agostino G, Calignano A, Rossi F, Di Marzo V, Maione S (2012) Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. Eur J Pharmacol 676:41–50. doi:10.1016/j.ejphar.2011.11.034
Smart D, Jonsson KO, Vandevoorde S, Lambert DM, Fowler CJ (2002) ‘Entourage’ effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Brit J Pharmacol 136:452–458. doi:10.1038/sj.bjp.0704732
Petrocellis D, Davis JB, Di Marzo V (2001) Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506:253–256. doi:10.1016/S0014-5793(01)02934-9)
Bíró T, Maurer M, Modarres S, Lewin E, Brodie C, Acs G, Acs P, Paus R, Blumberg PM (1998) Characterization of functional vanilloid receptors expressed by mast cells. Blood 91:1332–1340
Kim SR, Kim SU, Oh U, Jin BK (2006) Transient receptor potential vanilloid subtype 1 mediates microglial cell death in vivo and in vitro via Ca2+-mediated mitochondrial damage and cytochrome c release. J Immunol 177:4322–4329
Katsura H, Obata K, Mizushima T, Sakurai J, Kobayashi K, Yamanaka H, Dai Y, Fukuoka T, Sakagami M, Noguchi K (2006) Activation of Src-family kinases in spinal microglia contributes to mechanical hypersensitivity after nerve injury. J Neurosci 26:8680–8690. doi:10.1523/JNEUROSCI.1771-06.2006
Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83–87. doi:10.1038/384083a0
Ueda N, Yamanaka K, Yamamoto S (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276:35552–35557. doi:10.1074/jbc.M106261200
Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D (2009) Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci USA 106:20966–20971. doi:10.1073/pnas.0907417106
Saturnino C, Petrosino S, Ligresti A, Palladino C, De Martino G, Bisogno T, Di Marzo V (2010) Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. Bioorg Med Chem Lett 20:1210–1213. doi:10.1016/j.bmcl.2009.11.134
Yamano Y, Tsuboi K, Hozaki Y, Takahashi K, Jin XH, Ueda N, Wada A (2012) Lipophilic amines as potent inhibitors of N-acylethanolamine-hydrolyzing acid amidase. Bioorg Med Chem 20:3658–3665. doi:10.1016/j.bmc.2012.03.065
Li Y, Yang L, Chen L, Zhu C, Huang R, Zheng X, Qiu Y, Fu J (2012) Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds. PLoS One 7:8. doi:10.1371/journal.pone.0043023
David S, Kroner A (2011) Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci 12:388–399. doi:10.1038/nrn3053
Schäfer T, Starkl P, Allard C, Wolf RM, Schweighoffer T (2010) A granular variant of CD63 is a regulator of repeated human mast cell degranulation. Allergy 65:1242–1255. doi:10.1111/j.1398-9995.2010.02350.x
Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, Federico V, Petrucci M, Cruccu G (2011) Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disorders Drug Targets 10:916–920. doi:10.2174/187152711799219307
Kopsky DJ, Hesselink JM (2012) Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct Med 30:53–55. doi:10.1136/acupmed-2011-010119
Hesselink JM, Hekker TA (2012) Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res 5:437–442. doi:10.2147/JPR.S32143
Hesselink JMK (2012) New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. The Open Pain Journal 5:12–23
Clemente S (2012) Amytrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: a case report. CNS Neurol Disord Drug Targets 11:933–936. doi:10.2174/1871527311201070933
Acknowledgements
The authors wish to thank Stefano Lovison for excellent graphic design assistance. L. Facci was supported by Fondazione CARIPARO “Progetto Dottorati di Ricerca” Anno 2009.
Conflicts of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Skaper, S.D., Facci, L. & Giusti, P. Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator. Mol Neurobiol 48, 340–352 (2013). https://doi.org/10.1007/s12035-013-8487-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-013-8487-6